Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in Cirrhosis and Hepatic Encephalopathy
NCT02636647Phase 1Completed
- Sponsor
- Jasmohan Bajaj
- Start
- Oct 2015
- Primary completion
- Aug 2016
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fecal microbiome transplant in hepatic encephalopathy (HE) and Cirrhosis (2 arms), sponsored by Jasmohan Bajaj. Primary endpoint: Safety and tolerability at 5 months. Started Oct 2015; status: completed.
02
Drugs
fecal microbiome transplant
03
Conditions
hepatic encephalopathy (HE)Cirrhosis
Beyond the preview
Go deeper on NCT02636647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02636647.